Login to Your Account

Financings Roundup

Orexigen Adding $90M Publicly, Ready for Contrave CVOT Trial

By Jennifer Boggs
Managing Editor

Friday, December 16, 2011

Back in September, Orexigen Therapeutics Inc.'s CEO told BioWorld Today that the firm hoped to avoid a near-term financing by securing an ex-U.S. partnership to help offset costs for the large cardiovascular outcomes trial (CVOT) required by the FDA to get obesity candidate Contrave (naltrexone HCl/bupropion) over the finish line.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription